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Human h defensins contribute to the first line of defense against infection of the lung. Polymorphisms in these genes are therefore
potential modifiers of the severity of lung disease in cystic fibrosis. Polymorphisms were sought in the human h-defensin genes DEFB1,
DEFB4, DEFB103A, and DEFB104 in healthy individuals and cystic fibrosis (CF) patients living in various European countries.
DEFB1, DEFB4, and DEFB104 were very polymorphic, but DEFB103A was not. Within Europe, differences between control
populations were found for some of the frequent polymorphisms in DEFB1, with significant differences between South-Italian and Czech
populations. Moreover, frequent polymorphisms located in DEFB4 and DEFB104 were not in Hardy Weinberg equilibrium in all
populations studied, while those in DEFB1 were in Hardy Weinberg equilibrium. Sequencing of a monochromosomal chromosome 8
mouse–human hybrid cell line revealed signals for multiple alleles for some loci in DEFB4 and DEFB104, but not for DEFB1. This
indicated that more than one DEFB4 and DEFB104 gene was present on this chromosome 8, in agreement with recent findings that
DEFB4 and DEFB104 are part of a repeat region. Individual DEFB4 and DEFB104 PCR amplification products of various samples
were cloned and sequenced. The results showed that one DNA sample could contain more than two haplotypes, indicating that the
various repeats on one chromosome were not identical. Given the higher complexity found in the genomic organization of the DEFB4
and DEFB104 genes, association studies with CF lung disease severity were performed only for frequent polymorphisms located in
DEFB1. No association with the age of first infection by Pseudomonas aeruginosa or with the FEV1 percentage at the age of 11–13
years could be found.
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1 These authors equally contributed to the study.Humans have two classes of defensins, named a and h,
based on the arrangements of cysteines within their
sequences. a Defensins are expressed mainly in cells of
the immune system, like Paneth cells and neutrophils.
The expression of h defensins is restricted mainly to
epithelial cells that line the body and can be induced by
microorganisms and inflammatory factors. Their function05) 574 – 581
A. Vankeerberghen et al. / Genomics 85 (2005) 574–581 575in the immune system is dual. First, due to their positive
charge they can interact with and integrate into the
membrane of pathogens, including bacteria, fungi, and
enveloped viruses, to kill them. Second, they can attract
cells of the acquired immune system. DEFB4 can even
induce the maturation of dendritic cells and act as an
adjuvant. More than 30 potential h-defensin genes have
been identified in humans [2], but only 4 have been
studied in detail, DEFB1, DEFB4, DEFB103A, and
DEFB104. These genes are composed of two exons
and are located on chromosome 8p22–p23. DEFB4,
DEFB103A, and DEFB104 are clustered together at a
distance of ¨600 kb from DEFB1. Although the peptides
have similar structures, they seem to have specific
antimicrobial spectra and induction pathways [3]. An
upregulation of DEFB4 and DEFB103A is often seen in
inflamed tissues. High DEFB103A concentrations are
found in psoriasis plaques and increased concentrations of
DEFB4 peptides are found in plasma and bronchoalveolar
lavage fluid of patients with diffuse panbronchiolitis [4].
DEFB1 and DEFB4 peptides are detected in the lungs
[5,6].
Cystic fibrosis (CF) is caused by mutations in the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene, which encodes a chloride channel
expressed in epithelial cells lining most exocrine glands.
Defects in this protein are associated with recurrent lung
infections and pancreatic insufficiency. The severity of
lung disease does not always correlate well with the
CFTR genotype. Other environmental and genetic factors
affect the lung phenotype. Genes coding for mannose-
binding lectin, tumor necrosis factor a, and transforming
growth factor h1 have been reported as possible
modifier genes [7]. Since human h defensins form part
of our first line of defense in the lung, they are
potential modifier genes for cystic fibrosis lung disease.
At the start of this study, however, only four poly-
morphic loci, all located in DEFB1, had been reported
[8]. We therefore first sequenced the genomic region
harboring the DEFB1, DEFB4, DEFB103A , and
DEFB104 genes in detail in individuals derived from
various populations.
Frequent polymorphisms located in DEFB4 and
DEFB104 were not in Hardy Weinberg equilibrium in
all populations studied, while those in DEFB1 were all in
Hardy Weinberg equilibrium. To investigate this further,
the h-defensin region of a monochromosomal chromo-
some 8 hybrid was sequenced. In addition, individual
DEFB4 and DEFB104 PCR amplification products were
cloned and sequenced. The results will confirm the
results of Hollox et al. [1], that the DEFB4, DEFB103A,
and DEFB104 genes are part of a repeated genomic
region.
Finally, association studies of the frequent polymor-
phisms located in DEFB1 with the severity of the lung
disease were performed in cystic fibrosis patients.Results
Identification of nucleotide changes in DEFB1, DEFB4,
DEFB103A, and DEFB104 exons and their exon/intron
boundaries
The four h-defensin genes are each composed of two
exons. To identify nucleotide changes in these genes, their
exon and intron boundaries were amplified by PCR and
sequenced. Initially, four populations were included in the
study: a Belgian and South-Italian control population and
a Belgian and South-Italian CF population composed only
of patients homozygous for the F508del CFTR mutation.
The h-defensin mutations occurring at a frequency higher
than 5% are shown in Table 1. The nucleotides are
numbered at the transcript level according to the
published sequences DEFB1, GenBank U50930; DEFB4,
GenBank AF040153; DEFB103A, GenBank AF217245;
and DEFB104 [9], with nucleotide 1 being the first
nucleotide of exon 1.
DEFB1, DEFB4, and DEFB104 were found to be very
polymorphic (Table 1). DEFB103A, in contrast, was not
polymorphic at all: only 1 of the 350 DNA samples
harbored the nucleotide change 16T Y C (Table 2). The
most frequent nucleotide changes were located in the introns
and the 5V and 3VUTRs. The intron of DEFB4 harbored
frequent insertion polymorphisms: 81+160 ins T prolongs a
tract of 6 T to 7 T and 81+261 ins GTAGACTGA resulted in
a duplication of TAGACTGA separated by 1 G.
Defensin peptides are composed of a hydrophobic
prepro sequence, which is thought to regulate the process-
ing of the peptide, and a mature cationic sequence that
encodes the antimicrobial and chemotactic active form of
the protein. Most of the DEFB1 amino acid changes are
located in the mature part of the peptide (Table 2). In
DEFB4, only two missense mutations were found, which
were located in the prepro sequence (Table 2). Contrary to
DEFB1 and DEFB4, the missense mutations located in
DEFB104 were detected frequently. Moreover, R36C and
R38Q showed population differences in distribution: they
were found only once in the South-Italian control and CF
populations but at higher frequency in the Belgian and
Czech populations.
Population differences in haplotype and genotype
frequencies of DEFB1 polymorphisms
The distribution of the genotypes of all the frequent
DEFB1 polymorphisms were in Hardy Weinberg equili-
brium. Three polymorphisms located in the 3VUTR of
DEFB1 (at the polymorphic loci 16G/A, 24C/G, and
48A/G) have been reported to be observed on only three
possible haplotypes [8]. We could confirm this by
segregation analysis in 50 nuclear families (data not
shown). Moreover, we also found that an allele at a
fourth polymorphic locus was linked to this haplotype:
Table 2
Rare nucleotide changes (frequency <5%) in the human h-defensin genes
Location Polymorphic locusa Location Polymorphic locus
DEFB1 promoter 1–127A/T DEFB4 promoter 1–180A/C
DEFB1 promoter 1–113C/T DEFB4 promoter 1–179G/C
DEFB1 promoter 1–112G/A DEFB4 prepro sequence 39C/T (L6F)
DEFB1 promoter 1–69G/A DEFB4 prepro sequence 44C/T (L7L)
DEFB1 promoter 1–60G/A DEFB4 prepro sequence 65C/T (F14F)
DEFB1 intron 1 128+5G/A DEFB4 prepro sequence 71G/A (M16I)
DEFB1 intron 1 129–69C/T DEFB4 intron 1 81+145C/A
DEFB1 prepro sequence 131G/T (G22C) DEFB4 3VUTR 247C/G
DEFB1 mature sequence 168A/G (H34R) DEFB4 3VUTR 269A/G
DEFB1 mature sequence 171A/G (Y35C) DEFB4 3VUTR 304A/T
DEFB1 mature sequence 178C/T (C37C) DEFB4 intron 2 319+26G/A
DEFB1 mature sequence 179G/A (V38I)
DEFB1 mature sequence 217G/A (P50P) DEFB103A prepro sequence 16T/C (L6F)
DEFB1 mature sequence 266T/A (C67S)
DEFB1 3VUTR 300G/A DEFB104 promoter 1–23C/T
DEFB1 3VUTR 300G/C DEFB104 intron 1 72+2T/C
DEFB1 3VUTR 306G/C DEFB104 intron 1 72+147C/A
DEFB1 3VUTR 361A/G DEFB104 intron 2 285+57C/G
The amino acid changes are indicated in parentheses.
a The nucleotides are numbered at the transcript level according to the published sequences DEFB1, GenBank U50930; DEFB4, GenBank AF040153
DEFB103A, GenBank AF217245; and DEFB104 [9], with nucleotide 1 being the first nucleotide of exon 1. For mutations located in introns, the affected
nucleotide position respective to the first (minus sign) or last nucleotide (plus sign) of the closest exon is given. The possible nucleotides that can be found are
then given and separated by a slash.
Table 1
Frequent nucleotide changes (frequency >5%) in the human h-defensin genes
Location Polymorphism Control populations CF populations
Polymorphic locusa Allele Belgian S. Italian Czech Belgian S. Italian Czech
DEFB1 5VUTR 16G/A 16A 33.0% 44.5% 27.8% 40.3% 44.6% 39.1%
DEFB1 5VUTR 24C/G 24G 20.5% 18.5% 22.7% 19.4% 16.3% 22.5%
DEFB1 5VUTR 48A/G 48G 53.5% 63.0% 50.5% 59.7% 60.8% 61.6%
DEFB1 intron 1 128+19T/A 128+19A 19.5% 18.5% 22.7% 19.4% 16.3% 22.5%
DEFB1 intron 1 129–226T/C 129–226C 29.5% 34.5% 21.6% 34.4% 36.1% 30.4%
DEFB1 intron 1 129–170C/G 129–170G 29.0% 34.5% 21.6% 34.4% 35.5% 30.4%
DEFB1 3VUTR 279A/G 279G 80.0% 88.5% 74.7% 92.6% 91.0% 83.8%
DEFB4 promoter 1–85T/C 1–85C 39.2% 34.0% na 39.3% 32.1% na
DEFB4 intron 1 81+160 ins T 81+160 ins T 85.1% 83.7% na 76.2% 80.4% na
81+261 ins 81+261 ins
DEFB4 intron 1 GTAGACTGA GTAGACTGA 30.9% 35.7% na 31.8% 34.6% na
DEFB4 prepro sequence 107T/C (P28P) 107C 29.3% 28.0% 43.1% 36.9% 29.9% 42.9%
DEFB4 3VUTR 262C/T 262T 27.8% 24.5% 31.4% 29.5% 23.5% 29.3%
DEFB4 intron 2 319+3C/G 319+3G 23.7% 18.5% 31.4% 23.0% 17.9% 29.3%
DEFB4 intron 2 319+53G/A 319+53A 28.3% 24.0% 43.1% 37.7% 27.2% 42.1%
DEFB104 prepro sequence 42G/A (V10I) 42A (10I) 60.0% 53.0% na 54.5% 56.5% na
DEFB104 intron 1 73–192T/C 73–192C 37.5% 36.5% 40.4% 28.4% 39.4% 42.0%
DEFB104 intron 1 73–158A/G 73–158G 62.5% 63.0% 59.0% 60.5% 54.7% 57.9%
DEFB104 intron 1 73–114C/A 73–114A 43.0% 43.5% 39.4% 44.0% 39.4% 39.3%
DEFB104 intron 1 73–77C/T 73–77T 13.5% 11.5% 13.7% 9.7% 28.8% 12.0%
DEFB104 intron 1 73–29G/T 73–29T 52.5% 50.5% 50.0% 51.5% 51.2% 47.9%
DEFB104 mature sequence 120C/T (R36C) 120T (36C) 7.0% 1.5% 9.0% 9.0% 0.0% 12.7%
DEFB104 mature sequence 127G/A (R38Q) 127A (38Q) 9.5% 1.5% 18.0% 16.0% 0.0% 21.8%
DEFB104 intron 2 285+13C/T 285+13T 5.5% 10.5% 24.2% 3.0% 1.8% 28.9%
DEFB104 intron 2 285+26A/G 285+26G 57.0% 60.0% 60.0% 55.2% 60.0% 58.5%
DEFB104 intron 2 285+99C/T 285+99T 57.0% 60.0% 59.5% 55.2% 60.0% 58.5%
The frequencies of the polymorphic alleles are shown for the various populations (na, not analyzed). The amino acid changes are indicated in parentheses. The
polymorphic loci that are not in Hardy Weinberg equilibrium in the population are shown in bold.
a The nucleotides are numbered at the transcript level according to the published sequences DEFB1, GenBank U50930; DEFB4, GenBank AF040153;
DEFB103A, GenBank AF217245; and DEFB104 [9], with nucleotide 1 being the first nucleotide of exon 1. For mutations located in introns, the affected
nucleotide position respective to the first (minus sign) or last nucleotide (plus sign) of the closest exon is given. The possible nucleotides that can be found are
then given and separated by a slash.
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Table 4
Distribution of the frequent DEFB1 intron 1 and exon 2 polymorphic loci
Genotype Haplotype
TT TC CC T C
DEFB1 intron 1 129–226T/C
South-Italian controls
(n = 100)
43.00% 45.00% 12.00% 65.50% 34.50%
Czech controls
(n = 99)
60.00% 36.84% 3.16% 78.42% 21.58%
p value m2 test
Czech/S Italian
0.014 0.005
CC CG GG C G
DEFB1 intron 1 129–170C/G
South-Italian controls
(n = 100)
42.00% 44.00% 14.00% 64.00% 36.00%
Czech controls
(n = 99)
60.00% 36.84% 3.16% 78.42% 21.58%
p value m2 test
Czech/S Italian
0.006 0.002
AA AG GG A G
DEFB1 exon 2 279A/G
South-Italian controls
(n = 100)
1.00% 21.00% 78.00% 11.50% 88.50%
Czech controls
(n = 99)
8.42% 33.68% 57.89% 25.26% 74.74%
p value m2 test
Czech/S Italian
0.003 0.0004
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named A (16G-24C-48A-128+19T), B (16A-24C-48G-
128+19T), and C (16G-24G-48G-128+19A). When the
frequencies of the A, B, and C haplotypes were compared
between the Belgian and the South-Italian control and CF
populations, a distribution difference was observed
between the two control populations: the A haplotype
was more frequent in the Belgians and the B haplotype
more frequent in the South Italians. The two CF
populations, however, showed no significant differences
(Table 3). To analyze this difference in distribution
further, three additional populations were analyzed: a
Czech control and a Czech F508del/F508del CF popula-
tion and a North-Italian control population composed of
people living in the Northeast of Italy for at least three
generations. The CF populations again showed a similar
distribution. The North-Italian, Belgian, and Czech control
samples were similar to one another but different from the
South-Italian controls, with the A haplotype being more
frequent in the more northern European populations and
the B haplotype being more frequent in the south of Italy.
The difference was the largest between the Czechs and
the South Italians ( p = 0.0023). Polymorphisms located
in the second exon of DEFB1 also showed a difference in
distribution in South-Italian and Czech control populations
(Table 4): 129170G, 129226C, and 279G were more
frequent in the south of Italy.
Hardy Weinberg disequilibrium for polymorphisms in
DEFB4 and DEFB104
Most polymorphisms located in DEFB4 and DEFB104
and occurring at a frequency higher than 20% were not in
Hardy Weinberg equilibrium (Table 1). The observed
distribution and the expected Hardy Weinberg genotypeTable 3
Distribution of exon 1 genotypes and haplotypes in DEFB1 in control and CF pa
DEFB1 exon 1 ABC genotype
AA AB AC
Belgian controls (n = 100) 17.00% 36.00% 23.00%
South-Italian controls (n = 100) 18.00% 26.00% 12.00%
North-Italian controls (n = 99) 22.22% 32.32% 19.19%
Czech controls (n = 99) 23.23% 29.29% 23.23%
p value m2 test Belg/S Italian 0.031
p value m2 test Belg/Czech 0.77
p value m2 test Czech/S Italian 0.014
p value m2 test Belg/N Italian 0.436
p value m2 test N Italian/S Italian 0.098
p value m2 test Czech/N Italian 0.256
Belgian F508del patients (n = 61) 12.90% 41.94% 12.90%
South-Italian F508del patients (n = 82) 10.84% 44.58% 12.05%
Czech F508del patients (n = 69) 17.39% 27.54% 14.49%
p value m2 test Belg/S Italian 0.814
p value m2 test Belg/Czech 0.601
p value m2 test Czech/S Italian 0.159
A, 16G-24C-48A-128+19T; B, 16A-24C-48G-128+19T; C, 16G-24G-48G-128+1distributions for some of these polymorphisms in the
Belgian control population are shown in Fig. 1. The same
observation was made in all other populations. In essence,
the number of heterozygotes was higher and the number of
homozygotes was lower than expected. For some of the
polymorphisms, like 81+261 ins GTAGACTGA or
73192T/C, no homozygous variants could be observed.tients
DEFB1 exon 1 ABC haplotype
BB BC CC A B C
9.00% 12.00% 3.00% 46.50% 33.00% 20.50%
22.00% 19.00% 3.00% 37.00% 44.50% 18.50%
12.12% 14.14% 0.00% 47.98% 35.35% 16.67%
6.06% 14.14% 4.04% 49.49% 27.78% 22.73%
0.056
0.52
0.0023
0.608
0.078
0.158
11.29% 16.13% 4.84% 40.32% 40.32% 19.35%
13.25% 18.07% 1.20% 39.16% 44.58% 16.27%
17.39% 15.94% 7.25% 38.41% 39.13% 22.46%
0.739
0.766
0.381
9A. Significant values are shown in bold.
Fig. 1. Hardy Weinberg disequilibrium for some frequent polymorphisms located in DEFB4 (left) and DEFB104 (right). The genotype distribution of the
Belgian control samples is depicted with white bars; the expected Hardy Weinberg genotype distribution is depicted with black bars. The observed and
expected genotype distributions of each polymorphic locus were compared using m2 testing; the p values are indicated.
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DEFB104 genes, but not DEFB1, are part of a 240-kb
repeat unit found in 2 to 12 copies in a diploid genome
[1]. If some of the different copies, present on one
chromosome 8, harbor at least one polymorphism, then
that individual would be characterized as being hetero-
zygous in a sequencing assay. To analyze this, the DNA of
a monochromosomal hybrid containing only one chromo-
some 8 (hybrid panel Eurogen) was amplified for DEFB1,
DEFB4, and DEFB104 by PCR and sequenced. The
hybrid cell line contained only one sequence for DEFB1
but heterozygous signals were observed for one poly-
morphism in DEFB4 and six polymorphisms in DEFB104.
These results indicate that multiple different copies of
DEFB4 and DEFB104 can be present on one chromosome
8. DEFB1, which is located at a distance of ¨600 kb from
the repeat region, did not show more than one signal for
any of the DEFB1 polymorphisms.
To determine whether a DNA sample derived from an
individual could indeed contain more than two DEFB4 and
DEFB104 haplotypes, the DEFB4 and DEFB104 genes
were amplified by PCR with Pwo DNA polymerase for
eight individuals. This enzyme has proofreading activity
such that misincorporation of nucleotides during PCR
remains very low. Individual PCR fragments were then
cloned and sequenced. For each exon, 10 cloned PCR
fragments were sequenced and the haplotype of the exon
was determined. No polymorphisms other than those found
in the original DNA sample were found, indicating that Pwo
DNA polymerase did not introduce mistakes into the PCRfragments analyzed. The eight samples contained two to six
different DEFB4 exon 1 and exon 2 haplotypes and three to
seven different DEFB104 exon 2 haplotypes. An example
of the haplotype analysis of the cloned fragments for sample
6 is given in Table 5. Seven haplotypes for DEFB104 exon
2 were found, indicating that the DEFB104 region was
present in at least seven different copies on the two
chromosomes 8.
Association of DEFB1 polymorphisms with lung disease
severity in cystic fibrosis
Initially, this study was set up to analyze the influence of
polymorphisms in the human h defensins on the cystic
fibrosis lung phenotype. Given the more complex nature
that is now found for DEFB4, DEFB103A, and DEFB104,
and since we do not know the exact number of repeats in the
individuals in this study, association studies could not be
performed for DEFB4, DEFB103A, and DEFB104.
Association studies of DEFB1 polymorphisms with CF
lung disease severity could be performed since DEFB1 is not
part of this repeat region. Recurrent infections with
Pseudomonas aeruginosa result in increasing lung deterio-
ration. A lower age of first infection is generally associated
with worse outcome. Therefore, the different frequent
polymorphisms (>20%) located in DEFB1 were analyzed
for a possible correlation with an earlier, or later, age of first
infection by P. aeruginosa. The difference in the mean age of
first colonization of the different genotypes of the poly-
morphisms was analyzed using ANOVA. No association was
Table 5
Composition of the different repeat units of DEFB4 exon 1, DEFB4 exon 2,
and DEFB104 exon 2 found in one DNA sample
Haplotypes identified
DEFB4 exon 1
1–180A/C C A A A C
1–85T/C C T T T C
81+160 ins T Ins Ins No ins Ins No ins
81+261 ins
GTAGACTGA
No ins No ins No ins Ins No ins
DEFB4 exon 2
107T/C T C T T
319+26G/A A G G G
319+53G/A G A G A
DEFB104 exon 2
73–192T/C C T T T T C T
73–158A/G G A A G A G G
73–77C/T T C C C C C C
73–29G/T T G G T G G G
120C/T C C T C C C T
127G/A G A G G G A G
285+13C/T C T C C C T C
285+26A/G G G A G G G A
285+99C/T T T C T T T C
The polymorphic loci in this sample are depicted in the left column. The
identities of the different alleles found in the various single amplification
products derived from that DNA sample are indicated in the remaining
columns. Five different haplotypes were found for DEFB4 exon 1, four for
DEFB4 exon 2, and seven for DEFB104 exon 2.
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the age of presumed first P. aeruginosa infection.
The severity of lung disease is measured by the forced
expiratory volume in 1 s (FEV1). The FEV1 values at the
age of 12–14 were available for most patients and they were
calculated as FEV1% predicted according to Knudson et al.
[16]. No association was found between the frequent
polymorphisms (>20%) located in DEFB1 and FEV1%
for these patients.Discussion
During evolution, defensins have evolved by rounds of
duplication and selection, with rapid divergence of sequen-
ces encoding the mature protein, presumably to create
antimicrobial compounds that are more active and/or better
adapted, thereby strengthening the innate defenses of an
individual [10]. At the start of this study only four
polymorphic loci, all located in DEFB1, were known [8].
The sequencing results reported in this study show that
DEFB1, DEFB4, and DEFB104 are very polymorphic and
that DEFB103A is not polymorphic. In DEFB103A, only
one nucleotide change was found and this in only 1 of the
350 samples analyzed. DEFB103A has the highest anti-
microbial activity, in comparison to the other defensins
analyzed in this study [11]. DEFB103A also shows a
marked degree of conservation in humans, great apes, andNew and Old World monkeys [12]. These data might
indicate that this very active, and even salt-insensitive,
antimicrobial agent is very crucial in our defenses and that
mutations are not tolerated. This hypothesis requires,
however, further investigation.
The promoters of DEFB1 and DEFB4 harbored multiple
rare mutations. None of the changes found in the promoter
of DEFB4 affect NF-nB binding sites. NF-nB is a known
mediator of bacteria- and inflammation-induced DEFB4
expression. Multiple missense mutations were found at low
frequency in DEFB1. Only one was found in the pro
sequence and six were found in the mature sequence. V38I
has been detected in 2.8% of healthy Japanese individuals
and in 15% of Japanese COPD patients [13]. We observed
this mutation only once in a CF patient.
Population differences in the frequency of polymor-
phisms have been observed throughout the whole DEFB1
gene. Jurevic et al. [14] described differences in the
distribution of 16G/A, 48A/G, 128+19T/A, 279A/G, and
361A/G comparing Northern European, Afro-American,
Middle Eastern, Mexican, and Senegalese individuals. We
observed differences within European countries: the distri-
bution of these polymorphisms was similar between Czech,
Belgian, and North-Italian populations but differed signifi-
cantly from that of South Italians.
Most of the frequent DEFB4 and DEFB104 polymor-
phisms were not in Hardy Weinberg equilibrium in the
populations analyzed, while the DEFB1 polymorphisms
were all in Hardy Weinberg equilibrium. All these genes are
located on the short arm of chromosome 8, but DEFB4,
DEFB103A, and DEFB104 are clustered together at a
distance of ¨600 kb from DEFB1. Since the start of this
study, it was found that DEFB4, DEFB103A, and DEFB104
are part of a repeat unit of >240 kb that can be found at a
copy number of 2 to 12 in a diploid genome [1]. Sequencing
of a monochromosomal hybrid containing one chromosome
8 indeed showed 2 nucleotides for some polymorphic loci,
supporting this observation. Moreover, cloning and
sequencing of individual PCR fragments of DEFB4 exons
1 and 2 and of DEFB104 exon 2 showed that more than two
haplotypes can be present for the different exons in an
individual and that the repeats on one chromosome may
thus not be identical. In one DNA sample, even seven
different haplotypes for DEFB104 exon 2 were found.
When the frequency of these frequent polymorphisms was
analyzed in the different populations studied, Hardy Wein-
berg disequilibrium was found due to the fact that the
number of homozygotes was too low and the number of
heterozygotes was too high. This might be explained by the
fact that the various copies of the DEFB4–DEFB103A –
DEFB104 region present on one chromosome 8 might not
be identical. Indeed, from the moment that one of the
various repeats carries a different allele at a particular
polymorphic locus, the individual will be typed as hetero-
zygous for that polymorphic marker with a sequencing
assay. An individual will be typed as homozygous for a
A. Vankeerberghen et al. / Genomics 85 (2005) 574–581580polymorphic marker only if the same allele is found at that
polymorphic marker in all repeats.
h Defensins are part of our innate immune system. They
can kill microbes by integrating into the membrane of
bacteria, fungi, and enveloped viruses. Through their
chemotactic activity they form the link between the innate
and the acquired immune system. Polymorphisms in these
genes might therefore influence the clinical phenotype of
patients affected by lung diseases, as has been observed for
V38I in Japanese COPD patients. The DEFB1 24C/G
polymorphism has also been associated with low levels of
oral Candida [15]. The different frequent polymorphisms
(>20%) found in DEFB1 were analyzed for a possible
modulating role on CF lung disease severity. No association
was found between the tested DEFB1 polymorphisms with
the age of first infection by P. aeruginosa or with FEV1%.
Strangely enough the significant differences in DEFB1
polymorphisms observed between South Italians and other
European populations in the controls could not be confirmed
in the CF patients. This suggests that the CF patients of the
south of Italy represent a biased sample of the population.
Whether this is in any way related to the disease remains to
be determined.
Most of the frequent DEFB4 and DEFB104 polymor-
phisms were not in Hardy Weinberg equilibrium. Never-
theless the distribution of these polymorphisms was
significantly different between the CF patients and the
controls (data not shown). The interpretation of these
differences, however, will remain hazardous if no haplotype
analysis can be done. Complete characterization of the
number of repeats and of the polymorphisms they each carry
will be required before these data can be examined with
confidence.Materials and methods
Populations
For each population, i.e., Belgian, South Italian, North
Italian, and Czech, 100 DNA samples of individuals not
related to the cystic fibrosis patients were studied. For
association studies, 61 Belgian, 82 South-Italian, and 67
Czech CF patients were investigated. Only CF patients
homozygous for the F508del mutation were included. FEV1
values and age of first detected infection by P. aeruginosa
were taken from their clinical records. The FEV1 values were
normalized to FEV1% according to Knudson et al. [16].
DNA extraction and PCR
DNA was isolated from whole blood samples. The two
exons, and their exon/intron boundaries, of each h-defensin
gene were amplified in two PCRs (PCR primer sequences
available on request). For DEFB1 and DEFB4, 200 ng of
genomic DNA was used for PCR in a total volume of 50 Alcontaining 1 PCR buffer (Roche), 1.5 mM MgCl2, 200
AM dNTPs (Amersham Pharmacia), 10 pmol of each primer
(forward and reverse), and 1.75 U of AmpliTaq DNA
polymerase (Roche). Amplification was performed using
the following temperature profile: 5 min at 94-C; 35 cycles
composed of 30 s at 94-C, 30 s at 55-C, and 45 s at 72-C; 7
min at 72-C; and 15 min at 4-C. The PCR mixtures for
DEFB103A and DEFB104 included (in a final volume of 50
Al) 200 ng of DNA, 1 PCR buffer II (Applied Bio-
systems), 1.5 mM MgCl2, 250 AM dNTPs (Amersham
Pharmacia), 15 AM primers (forward and reverse), and 2 U
of Taq DNA polymerase (Applied Biosystems). A touch-
down PCR protocol was used: initial denaturation, 94-C for
3 min; amplification, 14 cycles of 94-C for 20 s, 62-C for
40 s, decreasing 0.5-C each cycle, 72-C for 45 s, and then
25 further cycles of 94-C for 20 s, 55-C for 40 s, 72-C for
45 s; final extension, 72-C for 7 min. All PCR amplifica-
tions were performed on a GeneAmp PCR System 9700
(Applied Biosystems). PCR amplification was checked by
2% agarose gel electrophoresis in 1 TBE.
Sequencing analysis
Sequence analysis of the PCR products, purified accord-
ing to Werle et al. [17], was performed on an automated
DNA sequencer (Applied Biosystems; Model 3100 genetic
analyzer). Cycle sequencing was performed directly on the
purified PCR product by BigDye terminator chemistry
according to the manufacturer’s recommendations (Applied
Biosystems; BigDye Terminator v3.0 Cycle Sequencing)
(sequencing primers available on request). All sequence
changes were confirmed on both strands. Sequencing of
DEFB4 exon 1 + intron 1 revealed an insertion poly-
morphism of 8 nucleotides, located near the 3V end of the
PCR product. To identify this polymorphism in the DNA
samples, an extra sequencing reaction was performed with a
forward internal primer.
Cloning of single PCR fragments
DEFB4 exon 1, DEFB4 exon 2, and DEFB104 exon 2
were amplified as described. The proofreading enzyme Pwo
DNA polymerase (Roche) was used instead of Taq DNA
polymerase. Amplified fragments were separated on a 1%
TBE–agarose gel, purified from the gel with the Qiaquick
gel extraction kit (Qiagen), ligated in pUC18 with the TOPO
cloning kit (Invitrogen), and transfected into Escherichia
coli cells as described by the manufacturer. The h-defensin-
plasmid from individual clones was amplified by colony
PCR and the h-defensin polymorphisms were identified by
sequencing of the PCR fragments.
Statistics
Statistical analysis was performed using ANOVA (Sys-
tatW5 program) to compare the means of groups of data and
A. Vankeerberghen et al. / Genomics 85 (2005) 574–581 581m2 analysis or Fisher’s exact test (Statcalc program) to
compare frequency data.Acknowledgments
The DNA of the monochromosomal hybrids was kindly
provided by Peter Marynen (University of Leuven, Louvain,
Belgium). Anne Vankeerberghen is a fellow of the Fonds
voor Wetenschappelijk Onderzoek Vlaanderen. These
investigations have been supported by an FWO grant
(G.0389.02N), the CF-PRONET grant (QLG1-CT-2001-
01005) from the European Commission, an Interuniversity
Poles of Attraction Program grant (P5/25-H), a grant (GOA
99/07) from the Onderzoeksraad KU Leuven, a grant from
the Alphonse and Jean Forton–Koning Boudewijn Stichting
(2000 14 R7115 B0), the Italian Ministry of University and
Research (FIRB 2001-2003), and MZ CR-00000064203,
1A/8336-3, MSMT CR-LN00A079, 111300003, EU CF
Chip, and CRMGEN. J.-J. Cassiman is the holder of the
Arthur Bax and Anna Vanluffelen Chair of Human
Genetics.References
[1] E.J. Hollox, J.A. Armour, J.C. Barber, Extensive normal copy number
variation of a beta-defensin antimicrobial-gene cluster, Am. J. Hum.
Genet. 73 (2003) 591–600.
[2] B.C. Schutte, et al., Discovery of five conserved beta-defensin gene
clusters using a computational search strategy, Proc. Natl. Acad. Sci.
USA 99 (2002) 2129–2133.
[3] T. Ganz, Defensins: antimicrobial peptides of innate immunity, Nat.
Rev. Immunol. 3 (2003) 710–720.
[4] T. Hiratsuka, et al., Increased concentrations of human beta-defensinsin plasma and bronchoalveolar lavage fluid of patients with diffuse
panbronchiolitis, Thorax 58 (2003) 425–430.
[5] M.J. Goldman, et al., Human beta-defensin-1 is a salt-sensitive
antibiotic in lung that is inactivated in cystic fibrosis, Cell 88 (1997)
553–560.
[6] R. Bals, et al., Human beta-defensin 2 is a salt-sensitive peptide
antibiotic expressed in human lung, J. Clin. Invest. 102 (1998)
874–880.
[7] F.J. Accurso, M.K. Sontag, Seeking modifier genes in cystic fibrosis,
Am. J. Respir. Crit. Care Med. 167 (2003) 289–290.
[8] T. Dork, M. Stuhrmann, Polymorphisms of the human beta-defensin-1
gene, Mol. Cell. Probes 12 (1998) 171–173.
[9] J.R. Garcia, et al., Human beta-defensin 4: a novel inducible peptide
with a specific salt-sensitive spectrum of antimicrobial activity,
FASEB J. 15 (2001) 1819–1821.
[10] C.A. Semple, M. Rolfe, J.R. Dorin, Duplication and selection in the
evolution of primate beta-defensin genes, Genome Biol. 4 (2003) R31.
[11] J. Harder, J. Bartels, E. Christophers, J.M. Schroder, Isolation and
characterization of human beta -defensin-3, a novel human inducible
peptide antibiotic, J. Biol. Chem. 276 (2001) 5707–5713.
[12] M. Boniotto, et al., A study of host defence peptide beta-defensin 3 in
primates, Biochem. J. 374 (2003) 707–714.
[13] I. Matsushita, et al., Genetic variants of human beta-defensin-1 and
chronic obstructive pulmonary disease, Biochem. Biophys. Res.
Commun. 291 (2002) 17–22.
[14] R.J. Jurevic, P. Chrisman, L. Mancl, R. Livingston, B.A. Dale,
Single-nucleotide polymorphisms and haplotype analysis in beta-
defensin genes in different ethnic populations, Genet. Test. 6 (2002)
261–269.
[15] R.J. Jurevic, M. Bai, R.B. Chadwick, T.C. White, B.A. Dale, Single-
nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-
throughput SNP assays and association with Candida carriage in
type I diabetics and nondiabetic controls, J. Clin. Microbiol. 41
(2003) 90–96.
[16] R.J. Knudson, M.D. Lebowitz, C.J. Holberg, B. Burrows, Changes in
the normal maximal expiratory flow-volume curve with growth and
aging, Am. Rev. Respir. Dis. 127 (1983) 725–734.
[17] E. Werle, C. Schneider, M. Renner, M. Volker, W. Fiehn, Convenient
single-step, one tube purification of PCR products for direct
sequencing, Nucleic Acids Res. 22 (1994) 4354–4355.
